BIOBRIEF
Eight large pharmaceutical companies have paid for early access to Vivodyne's twelve robotic labs and a tissue chip the size of a semiconductor wafer that hosts hundreds of living human tissues. Independent benchmarks are still pending.
Eight large pharmaceutical companies have paid for early access to Vivodyne's new "human biological datacenter," the company announced this week. Vivodyne says the system, built around twelve robotic HIVE laboratories and a new wafer-scale tissue chip, can run up to 3.1 million human-tissue experiments per year, a figure the company estimates is roughly twice the scale of every U.S. clinical trial combined.
The core unit is Series 2 TissueDisk, a biological chip that grows hundreds of large, living human tissues with perfusable blood vessels and organ-specific function. Each tissue is read out three ways: 3D confocal imaging, single-cell RNA sequencing, and 1,000-plex proteomic profiling. HIVE robots then run those tissues through weeks of autonomous drug and genetic-perturbation experiments, producing a closed-loop dataset that Vivodyne's team uses to train reinforcement-learning models, the same training paradigm that underpins large language models.
"This is needed more than ever, because we're running out of diseases that can be cured with the simple, single-target medicines of today," said CEO and co-founder Andrei Georgescu in the company's announcement.
Independent researchers have not yet benchmarked the platform. Existing organ-on-chip, organoid, and cell-foundation-model efforts, including work from competitors like BioMap, Recursion, and adjacent academic labs, already pursue related drug-discovery training loops, and the "first world model of human biology" framing is the vendor's, not the field's.